Akamai Technologies (AKAM) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.01%. A quarter ago, it was expected that this cloud services provider would post earnings of $1.64 per share when it actually produced earnings of $1.86, delivering a surprise of +13.41%.Over the last four q ...

Rimini Street (RMNI) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this company would post earnings of $0.1 per share when it actually produced earnings of $0.08, delivering a surprise of -20%.Over the last four quarters, the company has ...

Live Nation (LYV) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.20%. A quarter ago, it was expected that this ticket seller and concert promoter would post earnings of $1.21 per share when it actually produced earnings of $0.73, delivering a surprise of -39.67%.Over the last four qua ...

Texas Roadhouse (TXRH) came out with quarterly earnings of $1.28 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.50%. A quarter ago, it was expected that this restaurant chain would post earnings of $1.28 per share when it actually produced earnings of $1.25, delivering a surprise of -2.34%.Over the last four quarters, th ...

Sprouts Farmers (SFM) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.66%. A quarter ago, it was expected that this natural and organic food retailer would post earnings of $1.17 per share when it actually produced earnings of $1.22, delivering a surprise of +4.27%.Over the last fo ...

Ouster, Inc. (OUST) closed at $19.08 in the latest trading session, marking a +2.64% move from the prior day. This change outpaced the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.54%, while the tech-heavy Nasdaq lost 0.31%. Prior to today's trading, shares of the company had lost 26.49% lagged the Computer and Technology sector's loss of 3.36% and the S&P 500's loss of 0.76%.The upcoming earnings release of Ouster, Inc. will be of great interest to investors. The company's earnings report is ...

分组1 - LegalZoom reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, and down from $0.19 per share a year ago, representing an earnings surprise of -7.61% [1] - The company posted revenues of $190.27 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.22%, compared to year-ago revenues of $161.71 million [2] - LegalZoom shares have declined approximately 29.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $201.35 million, and for the current fiscal year, it is $0.74 on revenues of $802.25 million [7] - The Zacks Industry Rank indicates that the Industrial Services sector is currently in the bottom 32% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8]

分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

分组1 - Ardelyx reported break-even quarterly earnings per share, matching the Zacks Consensus Estimate of $0.02, with a year-ago comparison of $0.02 per share [1] - The company achieved revenues of $125.22 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.51% and showing an increase from $116.13 million year-over-year [2] - Ardelyx shares have increased approximately 15.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Ardelyx is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $111.28 million, and for the current fiscal year, it is $0.23 on revenues of $534.79 million [7] - The Medical - Drugs industry, to which Ardelyx belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - The 2025 Q4 earnings cycle has shown resilience with strong overall growth among S&P 500 companies, particularly highlighted by Cardinal Health (CAH) and Palantir (PLTR) delivering notably strong results [1][9]. Palantir Performance - Palantir reported sales of $1.4 billion, reflecting a 70% year-over-year growth, with U.S. sales reaching $1.1 billion, up 93% year-over-year and 28% sequentially [2][3]. - The company secured over $4.2 billion in total contract value (TCV), marking an increase of more than 130% from the previous year [3]. - Palantir's customer base expanded by 34% compared to the year-ago period [3]. Cardinal Health Performance - Cardinal Health achieved a double-beat relative to consensus expectations, with sales increasing by 18.8% year-over-year and adjusted EPS growing by 36.3% year-over-year [10]. - The growth was broad-based, particularly in Pharmaceuticals and Specialty Solutions, which saw a 19% year-over-year increase and accounts for approximately 90% of total sales [11]. - Following the strong quarterly performance, Cardinal Health raised its FY26 outlook, projecting adjusted EPS in the range of $10.15 - $10.35, indicating a 24.5% year-over-year growth [12].